Financial Performance - Total revenue for Q3 2025 was $4.815 million, a 139.5% increase from $2.014 million in Q3 2024[10] - Fitness product revenue reached $4.553 million in Q3 2025, up 181.5% from $1.617 million in Q3 2024[10] - Gross profit for Q3 2025 was $825 thousand, compared to a gross loss of $288 thousand in Q3 2024[10] - Net loss for Q3 2025 was $5.231 million, an improvement from a net loss of $7.141 million in Q3 2024[10] - The net loss for the nine months ended September 30, 2025, was $14,012,000, compared to a net loss of $29,172,000 for the same period in 2024, representing a 52% improvement[17] - The net loss for the three months ended September 30, 2025, was $5.231 million, compared to a net loss of $7.141 million for the same period in 2024, representing a 26.7% improvement[62] Assets and Liabilities - Total current assets increased to $17.372 million as of September 30, 2025, from $8.218 million as of December 31, 2024[8] - Total liabilities rose to $67.981 million as of September 30, 2025, compared to $27.055 million as of December 31, 2024[8] - The company reported a total stockholders' equity of $14.857 million as of September 30, 2025, up from $7.115 million as of December 31, 2024[8] - Digital assets increased to $36.770 million as of September 30, 2025, with no digital assets reported as of December 31, 2024[8] - The company has total outstanding debt of approximately $46.4 million as of the issuance date, with about $12.4 million scheduled to mature over the next twelve months[38] Cash Flow and Investments - Cash used in operating activities for the nine months ended September 30, 2025, was $8,161,000, slightly better than $8,909,000 used in the same period of 2024[17] - The company reported a significant cash outflow of $53,490,000 in investing activities for the nine months ended September 30, 2025, compared to $1,407,000 in 2024, primarily due to the acquisition of digital assets[17] - Financing activities generated $62,248,000 in cash for the nine months ended September 30, 2025, compared to $12,947,000 in 2024, indicating a strong capital influx[17] Stock and Equity - The weighted average common stock outstanding for Q3 2025 was 1,682,660 shares, compared to 4,653 shares in Q3 2024[10] - The company issued 1.5 million shares of Series A preferred stock upon conversion of debt[14] - The company issued common stock upon the exercise of stock options, resulting in $373,000[14] - The company issued 1,250,000 shares of Series LTI Convertible Preferred Stock valued at $2.5 million to executive officers and board members, which vests 100% upon grant date[87] Acquisitions - The Company completed the acquisition of Wattbike Holdings Limited for a total purchase price of approximately $4.0 million on July 1, 2025[30] - The Company completed the acquisition of CLMBR, Inc. for a total purchase price of approximately $16.1 million on February 2, 2024[32] - The company plans to acquire approximately 99.8% stake in Sportstech with an initial investment of $15,000,000 through the issuance of Series D Non-voting Convertible Preferred Stock[24] Research and Development - Research and development expenses decreased to $404 thousand in Q3 2025 from $2.212 million in Q3 2024[10] - Research and development expenses for the three months ended September 30, 2025, were $337,000, down from $1.006 million in the same period of 2024, a decrease of 66.5%[62] Digital Assets - The company recognized a change in fair value of digital assets amounting to $10.605 million for the three months ended September 30, 2025[62] - The company recognized a loss of $10.6 million and $10.5 million related to changes in the fair value of digital assets for the three and nine months ended September 30, 2025, respectively[197] - The company’s digital assets are categorized as Level 1 investments, with a total value of $36,770,000 as of September 30, 2025[195] Compliance and Regulatory Issues - The Company has received two notices from Nasdaq regarding noncompliance with listing requirements, but has since regained compliance with both[40] - The Company is subject to a Mandatory Panel Monitor for compliance with Nasdaq listing rules for one year following the compliance letters received[40] - The Company has been unable to remain in compliance with certain Nasdaq qualifications in the past, raising doubts about its ability to continue as a going concern[41] Debt and Interest - The company incurred interest expense of $4.017 million for the three months ended September 30, 2025, compared to $1.831 million in the same period of 2024, reflecting a 119% increase[62] - The company has limited available liquidity of approximately $0.6 million of unrestricted cash and cash equivalents to fund operations over the next twelve months[38] - The company recorded a gain on extinguishment of $0.3 million from the troubled debt restructuring of promissory notes[90] Miscellaneous - The company operates primarily in the United States, the United Kingdom, and Taiwan, with most long-lived assets held in the United States as of September 30, 2025[46] - The company expects to hold its digital assets as a long-term investment, classifying them as non-current assets as of September 30, 2025[50]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-39819 GLOBAL GAS CORPORATION (Exact name of registrant as specified in its charter) Delaware 85-1617911 (State or other jurisdiction of incorporation or ...

Financial Performance - As of September 30, 2025, the Company generated $33,012 in revenue for the nine months, compared to $0 for the same period in 2024[115] - General and administrative expenses increased by 17% to $142,286 for the three months ended September 30, 2025, compared to $121,207 for the same period in 2024[113] - The net loss for the three months ended September 30, 2025, was $161,170, representing a 30% increase from the net loss of $123,954 in the same period of 2024[113] - The Company had $48,307 in cash and cash equivalents and a working capital deficit of $307,470 as of September 30, 2025[121] - Net cash used in operating activities for the nine months ended September 30, 2025, was $63,632, a significant improvement compared to $1,265,884 for the same period in 2024[125][126] - The change in fair value of derivative warrant liabilities for the nine months ended September 30, 2025, was a loss of $8,090, compared to a gain of $357,080 in the same period of 2024[120] - The Company incurred $11,220 in interest expense for the nine months ended September 30, 2025, compared to $0 for the same period in 2024[119] Business Strategy - The Company is targeting both privately- and publicly-funded hydrogen development projects, supported by government incentives in North America and Western Europe[108] - The growth strategy includes placing modular generation and recovery solutions closer to end customers to reduce costs and improve pricing competitiveness[108] - The Company plans to own and operate hydrogen generation plants and sell the resulting industrial gas, requiring relevant licensing on a project-by-project basis[142] Regulatory and Compliance - Compliance with government regulations is necessary for the construction of hydrogen production facilities, including local zoning and permitting requirements[144] - The company is classified as an "emerging growth company" and has elected to take advantage of an extended transition period for complying with new or revised accounting standards[139] Challenges and Intellectual Property - The Company has not yet successfully closed on any project, indicating ongoing challenges in contract negotiations[109] - The company does not currently hold material intellectual property beyond certain logos and domain names[141] Environmental Initiatives - The company intends to deploy carbon recovery systems to significantly reduce or eliminate CO2 emissions during hydrogen production[143]

Revenue Performance - Revenues for Q3 2025 reached $2.0 million, reflecting a 95% sequential increase over Q2 2025, driven by higher equipment purchases and strong BIT™ Solution sales[6] - Net sales for the three months ended September 30, 2025, were $2,011,556, down 20.9% from $2,542,251 in the same period of 2024[27] - SteraMist solution sales increased by 21% year over year for the nine months ended September 30, 2025[6] Profitability and Margins - Gross profit margin remained strong at 61% for Q3 2025, consistent with the same period last year, indicating operational efficiency[6] - Gross profit for the nine months ended September 30, 2025, was $2,860,840, a decrease of 30.0% compared to $4,086,311 in 2024[27] - The company reported a net loss of $450,348 for the three months ended September 30, 2025, compared to a net income of $58,962 in the same period of 2024[27] Expenses and Liabilities - Operating expenses increased to $5,069,409 for the nine months ended September 30, 2025, compared to $5,041,873 in 2024, reflecting a rise of 0.5%[27] - The company incurred interest expenses of $130,339 for the three months ended September 30, 2025, compared to $93,620 in the same period of 2024, representing an increase of 39.2%[27] - Total liabilities increased from $5,594,799 in December 2024 to $5,838,709 in September 2025, an increase of approximately 4.4%[25] Shareholder Equity and Capital - Shareholders' equity decreased significantly from $4,098,939 in December 2024 to $2,206,482 in September 2025, a decline of about 46.1%[25] - As of September 30, 2025, the company had working capital of $2.5 million, with cash used in operations improving by approximately $876,000 compared to the same period in 2024[7] - An equity line of credit allows the company to sell up to $20 million of common stock over a 24-month period, enhancing financial flexibility[8] Market Presence and Future Outlook - International revenue accounted for nearly 36% of Q3 revenue, up from 20% in Q2 2025, highlighting the company's expanding global market presence[6] - The company's sales order backlog grew to $0.9 million at quarter-end and expanded to $1.3 million as of October 31, with approximately $3 million in pending contracts expected to close before year-end[6] - The potential demand for TOMI's product offerings is estimated at approximately $15 million, with $7 million designated as high priority[6] - The company expects to file a universal shelf registration statement allowing it to offer and sell securities up to $50 million, including the $20 million under the equity line of credit[9] Research and Development - Research and development expenses for the nine months ended September 30, 2025, were $139,380, down 25.0% from $185,923 in 2024[27] Installations and Product Development - The company completed major SteraMist® installations, including the first installation of the SteraMist Integration System – Standalone (SIS-SA) in the life sciences sector[6]

Financial Performance - Verrica reported $14.3 million in total revenue for Q3 2025, with $3.6 million from YCANTH® and $10.7 million from license and collaboration revenue[1]. - Total revenue for the nine months ended September 30, 2025, reached $30.485 million, up from $7.222 million in the same period of 2024, indicating a growth of approximately 322%[23]. - Product revenue for the three months ended September 30, 2025, was $3.607 million, compared to a loss of $1.865 million in the same period of 2024, representing a significant increase[21]. - For Q3 2025, net loss was $0.3 million, or $0.03 per share, compared to a net loss of $22.9 million, or $4.88 per share, for the same period in 2024[12]. - The net loss for the three months ended September 30, 2025, was $274 thousand, a substantial improvement from a net loss of $22.860 million in the same period of 2024[21]. - Non-GAAP adjusted net income for the three months ended September 30, 2025, was $1.194 million, compared to a non-GAAP adjusted net loss of $20.180 million in the same period of 2024[27]. Revenue Sources - License and collaboration revenue for the nine months ended September 30, 2025, was $18.9 million, compared to $1.0 million for the same period in 2024[13]. - The company received a $10 million cash milestone payment for the approval of YCANTH for molluscum in Japan[1]. Expenses - Selling, general and administrative expenses decreased to $9.4 million in Q3 2025 from $16.1 million in Q3 2024, a reduction of $5.6 million[12]. - Research and development expenses were $2.2 million for Q3 2025, compared to $2.4 million for the same period in 2024[12]. - Total operating expenses for the nine months ended September 30, 2025, were $35.478 million, a decrease from $61.731 million in the same period of 2024, reflecting a reduction of approximately 43%[23]. Product Development - YCANTH® (VP-102) is the first FDA-approved product for treating molluscum contagiosum, affecting approximately 6 million people in the U.S., primarily children[15]. - The company plans to launch YCANTH Rx, a new non-dispensing pharmacy option, in Q4 2025[10]. - The company plans to launch YCANTH Rx in the fourth quarter of 2025, with expectations for future commercial growth[19]. - The FDA provided positive feedback on the study design for a Phase 3 program for VP-315 in basal cell carcinoma, with a primary endpoint of complete clearance assessed at week 14[10]. - VP-315, a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy, is being developed for non-melanoma skin cancers, with a focus on basal cell and squamous cell carcinomas[16]. Cash Position - As of September 30, 2025, Verrica had $21.1 million in cash and cash equivalents[12]. - The company’s cash and cash equivalents decreased to $21.097 million as of September 30, 2025, down from $46.329 million at the end of 2024[25]. Stockholders' Equity - The company reported a total stockholders' deficit of $17.040 million as of September 30, 2025, compared to a deficit of $9.860 million at the end of 2024[25]. Product Dispensation - The company dispensed 37,642 applicator units of YCANTH for the nine months ending September 30, 2025, representing a 120% increase compared to 17,119 units in the prior year[3].

Business Growth and Strategy - Cycurion reported significant growth driven by organic business solutions and strategic acquisitions in the cybersecurity sector[250]. - The company has established a Master Service Agreement with SLG Innovation, which now represents a majority of Cycurion's revenues[260]. - Cycurion acquired technology assets from Sabres, enhancing its Cycurion Security Platform with Multi-Dimensional Protection, Web Application Firewall, and Bot Mitigation capabilities[265]. - The company anticipates closing the RCR Term Sheet transactions in the second half of the current fiscal year, which involves acquiring accounts receivable from SLG[261][263]. - Cycurion's subsidiaries include Axxum Technologies and Cloudburst Security, which provide cybersecurity services to federal and commercial clients[250][252]. - The company aims to maintain high client retention rates and efficiently acquire customers to support its growth strategy[246]. - The company is focused on expanding its commercial business through enhanced service offerings from the integrated Sabres technology[268]. - Cycurion's growth strategy includes attracting and retaining qualified cybersecurity talent to support its operations and expansion plans[246]. Financial Performance - Cycurion's financial performance in Q3 2025 reflects the impact of strategic acquisitions and operational efficiencies[269]. - Net revenues for the three months ended September 30, 2025, decreased by $0.6 million or 13.9% compared to the same period in 2024, and for the nine months ended September 30, 2025, revenues decreased by $2.1 million or 15.4%[271]. - Gross profit for the three months ended September 30, 2025, was $270,479, resulting in a gross profit percentage of 7.1%, down from 16.1% in the same period of 2024[270]. - Selling, general and administrative expenses increased significantly to $2,719,600 for the three months ended September 30, 2025, compared to $299,233 in the same period of 2024[274]. - Stock compensation expenses rose to $2,082,000 for the three months ended September 30, 2025, reflecting new compensation agreements with executives[275]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $8.8 million, compared to $1.2 million for the same period in 2024, primarily due to additional merger expenses[281]. - As of September 30, 2025, the company had $3.7 million in cash and cash equivalents, an increase of $3.6 million from approximately $38,742 as of December 31, 2024[286]. - The accumulated deficit increased to approximately $21.8 million as of September 30, 2025, compared to $3.2 million as of December 31, 2024, due to net losses during the nine months[285]. - For the nine months ended September 30, 2025, net cash provided by financing activities was $10.8 million, including $5.9 million from an equity line of credit[283]. - The company expects continued significant operating losses for the next few years and is dependent on obtaining additional financing to continue operations[286]. - The total assets increased to approximately $32.3 million as of September 30, 2025, from approximately $25.6 million as of December 31, 2024, primarily due to increases in goodwill[286].

Business Growth and Strategy - Cycurion reported significant growth driven by organic business solutions and strategic acquisitions in the cybersecurity sector[250]. - The company aims to close the RCR Term Sheet transactions in the second half of the current fiscal year, which involves acquiring accounts receivable from SLG[263]. - Cycurion's growth strategy includes expanding its commercial business through enhanced service offerings and integration of acquired technologies[268]. - The company is focused on maintaining high client retention rates and efficiently acquiring new customers in the cybersecurity market[246]. - Cycurion is actively seeking to attract and retain qualified cybersecurity talent to support its growth initiatives[246]. Acquisitions and Partnerships - The company has established a Master Service Agreement with SLG Innovation, which now represents a majority of Cycurion's revenues[260]. - Cycurion acquired technology assets from Sabres, enhancing its Cycurion Security Platform with Multi-Dimensional Protection, Web Application Firewall, and Bot Mitigation capabilities[265]. - The Cycurion Security Platform utilizes a proprietary cloud-based AI algorithm to improve cybersecurity measures in real-time[266]. - Cycurion's subsidiaries include Axxum Technologies and Cloudburst Security, both of which have established a strong presence in federal government contracts[252][253]. Financial Performance - Net revenues for the three months ended September 30, 2025, decreased by $0.6 million or 13.9% compared to the same period in 2024, and for the nine months ended September 30, 2025, revenues decreased by $2.1 million or 15.4%[271]. - Gross profit for the three months ended September 30, 2025, was $270,479, representing a gross profit percentage of 7.1%, down from 16.1% in the same period of 2024[270]. - Total operating expenses for the nine months ended September 30, 2025, were $19,578,880, significantly higher than $973,000 for the same period in 2024, primarily due to increased SG&A and stock compensation expenses[270]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $8.8 million, compared to $1.2 million for the same period in 2024, driven by additional merger expenses[281]. - The company incurred an accumulated deficit of approximately $21.8 million as of September 30, 2025, compared to $3.2 million as of December 31, 2024[285]. - Interest expense for the three and nine months ended September 30, 2025, was $712,374 and $1.5 million, respectively, compared to $319,666 and $1.0 million for the same periods in 2024[278]. - The company expects continued significant operating losses for the next few years, indicating a need for additional financing to sustain operations[286]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was $10.8 million, including proceeds from equity lines and convertible notes[283]. - The company completed a business combination with Western Acquisition Ventures Corp. in Q1 2025, contributing to increased operational expenses[276].

Financial Performance - Net revenues for Q3 2025 were $34,186,000, a decrease of 71.1% compared to $118,292,000 in Q3 2024[25] - Net loss attributable to GoHealth, Inc. for Q3 2025 was $165,846,000, compared to a net income of $6,775,000 in Q3 2024[25] - The company reported a comprehensive loss of $313,830,000 for Q3 2025, compared to a comprehensive income of $15,386,000 in Q3 2024[29] - For the three months ended September 30, 2025, the net loss was $313.9 million, compared to a net income of $15.4 million for the same period in 2024[35] - The total stockholders' equity decreased to $6.9 million as of September 30, 2025, down from $345.3 million a year earlier[35] - For the nine months ended September 30, 2025, GoHealth reported a net loss of $439.693 million, compared to a net loss of $65.294 million for the same period in 2024, indicating a significant increase in losses[42] - The company experienced a net loss of $313.9 million for the three months ended September 30, 2025, compared to a net income of $15.4 million in the prior year[183] Operating Expenses - Total operating expenses for Q3 2025 were $322,103,000, an increase of 100.0% from $160,964,000 in Q3 2024[25] - The loss from operations for the three months ended September 30, 2025, was $287.9 million, compared to a loss of $42.7 million in the prior year[164] - Marketing and advertising expenses for Q3 2025 were $17,471,000, a decrease of 61.5% from $45,270,000 in Q3 2024[25] - General and administrative expenses increased by 61.5% to $27.7 million for the three months ended September 30, 2025, up from $17.1 million in 2024[171] - Consumer care and enrollment expenses fell by 62.2% to $17.2 million for the three months ended September 30, 2025, compared to $45.6 million in 2024[168] Impairment Charges - The company incurred impairment charges of $206,163,000 in Q3 2025, with no such charges reported in Q3 2024[25] - The Company recorded long-lived asset impairment charges of $206.2 million and $260.0 million for the three and nine months ended September 30, 2025, respectively[221] - The Company recognized intangible asset impairment charges of $179.0 million and $232.0 million for the three and nine months ended September 30, 2025, respectively, to write down indefinite-lived trade names and definite-lived amortizable intangible assets[66] - Operating lease impairment charges amounted to $4.5 million for the three months and $5.3 million for the nine months ended September 30, 2025, due to cost-saving initiatives[222] Cash and Liquidity - Cash and cash equivalents decreased to $32,076,000 as of September 30, 2025, down from $40,921,000 at the end of 2024[31] - The company is actively pursuing strategic alternatives, including refinancing and cost management initiatives, to address liquidity concerns[53] - GoHealth's cash management initiatives are aimed at maintaining compliance with its debt covenants amid significant financial challenges[53] - The Company plans to focus on customer retention and cash preservation, expecting reduced revenues compared to the previous year due to scaled-back Medicare Advantage activities[154] Debt and Financing - The carrying value of the Company's long-term debt as of September 30, 2025, was $581.8 million, an increase from $487.4 million as of December 31, 2024[67] - The Company has a term loan facility with a principal amount of $636.5 million as of September 30, 2025, with scheduled repayments starting in 2025[67] - The Superpriority Credit Agreement was established on August 6, 2025, with a total principal amount of $115.0 million, including $80.0 million in new-money term loans and $35.0 million in roll-up term loans[74] - The Company recognized an aggregate loss on extinguishment of debt of $1.7 million and recorded debt discounts of $25.1 million related to the Class A common stock issued as non-cash consideration[78] Revenue Sources - Medicare agency revenue for the three months ended September 30, 2025, was $26.3 million, down from $92.3 million in the same period of 2024[117] - Total Medicare revenue for the nine months ended September 30, 2025, was $331.7 million, down from $406.7 million in the same period of 2024[117] - Significant customers included United, which represented 33.1% of total net revenues for the three months ended September 30, 2025, up from 25.9% in 2024[131] Employee and Organizational Changes - Management implemented a reduction in force impacting approximately 487 employees to improve cash flows and reduce operating expenses[53] - A workforce reduction impacting approximately 487 employees was announced on November 3, 2025, as part of cost-saving measures amid market conditions[148] - The Company established a "Transformation Committee" to explore strategic alternatives, including mergers and acquisitions, to enhance financial flexibility and stockholder value[156] Shareholder Information - The weighted-average shares of Class A common stock outstanding were 14,136,000 for Q3 2025, compared to 10,077,000 for Q3 2024[25] - The Company issued 4,766,219 shares of Class A common stock, representing 19.99% of the total issued and outstanding shares, as part of the amendment to the Existing Credit Agreement on August 6, 2025[109] - The initial liquidation preference for the Series A redeemable convertible preferred stock is $1,000 per share, with an annual dividend rate of 7.0%[98] Future Outlook - The Company is currently assessing the impact of recent accounting pronouncements on its disclosures, including ASU 2023-09 and ASU 2024-03[56][57] - The Company is actively looking to terminate or sublease certain office spaces and call centers as part of its cost-saving initiatives[62] - The Company’s revised long-term forecasts reflect a pullback on Medicare Advantage activity due to tightening health plan economics[223]

Financial Performance - The net loss for the quarter ended September 30, 2025, was $11.9 million, or $0.13 per share, compared to a net loss of $5.8 million, or $0.65 per share for the same quarter in 2024, indicating an increase in net loss of 105.2%[5] - The total net loss for the nine months ended September 30, 2025, was $35.5 million, or $0.40 per share, compared to a net loss of $15.4 million, or $2.03 per share for the same period in 2024, representing an increase of 130.5%[5] Cash and Securities - As of September 30, 2025, the company's cash, cash equivalents, and marketable securities totaled $77.3 million, down from $97.5 million as of December 31, 2024, representing a decrease of approximately 20.5%[4] Expenses - Research and development expenses for the quarter ended September 30, 2025, were $7.6 million, up from $4.2 million in the same quarter of 2024, reflecting an increase of 80.9%[6] - Selling, general and administrative expenses for the quarter ended September 30, 2025, were $5.6 million, compared to $1.6 million for the same quarter in 2024, marking an increase of 250%[8] - The company incurred a non-cash write-off of in-process research and development of $7.4 million for the nine months ended September 30, 2025, related to the acquisition of CorHepta[6] Clinical Development - The company plans to initiate its Phase 2b clinical study of IKT-001 in Pulmonary Arterial Hypertension (PAH) during the fourth quarter of 2025, with approximately 150 participants expected[3] Strategic Initiatives - The company appointed Timothy Pigot as Chief Commercial and Strategy Officer to enhance its strategic direction[7] - The company expects to present at the Jefferies Global Healthcare Conference in London on November 17, 2025, to discuss its developments and strategies[7] Liabilities - The total liabilities as of September 30, 2025, were $6.7 million, compared to $3.7 million as of December 31, 2024, indicating an increase of 79.5%[14]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ to _ Commission file number: 0-26680 OLD MARKET CAPITAL CORPORATION (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdict ...